156 results on '"Fedele, Palma"'
Search Results
2. Trastuzumab Deruxtecan in brain metastases from breast cancer: outcome analysis of real life population
3. Immunonutrition, Metabolism, and Programmed Cell Death in Lung Cancer: Translating Bench to Bedside
4. Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study.
5. Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study.
6. Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy.
7. De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?
8. Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)
9. Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response
10. What the future holds: BBT-176, beyond third-generation EGFR tyrosine kinase inhibitors
11. Antibody–Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading?
12. The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions
13. Stand der Forschung und neue therapeutische Perspektiven in der Immuntherapie des Prostatakarzinoms
14. Immunotherapy and Pancreatic Cancer: A Lost Challenge?
15. Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment
16. The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
17. Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?
18. Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs
19. Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
20. Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer
21. Tailoring antiHer2 treatment strategies in breast cancer and beyond
22. Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives.
23. Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities
24. Edmonton Symptom Assessment Scale may reduce medical visits in patients undergoing chemotherapy for breast cancer
25. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: Where are we now and where are we going?
26. "Exceptional Long Term Complete Response to Metronomic Chemotherapy in Advanced Breast Cancer"
27. Exceptional long term complete response to metronomic chemotherapy in advanced breast cancer
28. Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience
29. Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
30. Exploring metastatic breast cancer treatment changes during COVID-19 pandemic
31. Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience
32. efficacy of the association lorazepam plus dexamethasone plus granisetron in the control of acute chemotherapy induced nausea and vomiting (ACINV)
33. Exploring metastatic breast cancer treatment changes during COVID-19 pandemic.
34. A clinical evaluation of treatments that target cell cycle machinery in breast cancer
35. Final results of a prospective study of scalp cooling in preventing chemotherapy-induced alopecia
36. CDK4/6 inhibitors for hormone receptor-positive HER2-negative metastatic breast cancer: does one size fit all?
37. Pharmacotherapeutic options for patients with refractory breast cancer
38. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE
39. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
40. An update on first line therapies for metastatic breast cancer
41. Targeting triple negative breast cancer with histone deacetylase inhibitors
42. Chemotherapy induced-hair loss: A digni-life with DigniCap— Our experience and patient’s satisfaction.
43. Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience
44. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)‐ERIBE.
45. Response of Extensive Breast Cancer Skin Metastases to Rechallenge with Trastuzumab Together with Low-Dose Chemotherapy and Insulin
46. A multicenter phase II trial of nab‐paclitaxel and capecitabine in HER‐2 negative and triple‐ negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?
47. Evaluation of two different doses of weekly nab-paclitaxel (NP) in older breast cancer (BC) patients (pts).
48. Manageable treatment with lapatinib and continuous metronomic capecitabine in HER2 positive advanced breast cancer (ABC): Efficacy and safety data.
49. BMI variation increases recurrence risk in women with early-stage breast cancer
50. Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.